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were neutropenic (47%). The underlying disease was 
leukemia (47%) solid tumor (38%), and lymphoma 
(16%). Most (64%) of these pts with C. glabrata fungemia 
received fluconazole prophylaxis prior to the onset of 
fungemia. Disseminated infection occurred in 37 pts 
(39%), while 15% of all C. glabrata fungemia infections 
were catheter-related. Breakthrough candidemia on 
amphotericin B or liposomal compound regimen occur- 
red in 10 pts, 5 of whom had disseminated infection. C. 
glabrata fungemia was the primary cause of death in 13 
pts (14%) and was a contributory factor to death in 29 
other pts (39%). In conclusion, C. glabrata fungemia in 
immunocompromised cancer pts is associated with a high 
frequency of dissemination and mortality. This infection 
should be considered in any febrile neutropenic immuno- 
compromised cancer pt receiving fluconazole. 
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Two hundred and sixty episodes of FN in 149 children 
(aged 1.5-16 years), with acute myeloblastic leukemia 
(AML-43 cases) and acute lymphoblastic leukemia 
(ALL-106 cases) during the last 10 years were analyzed. 
Cytostatic therapy consist of mBFM-87 AML and 
mBFM-90 ALL protocols. The fourth degree of FN 
occured in 90% of cases of AML and in 53% of 
ALL. The infection sites\diseases were: blood + central 
venous catheter 12.3%, respiratory tract (pneumonias) 
18.8%, enteritidis 8.1%, stomatitis 5.4%, soft tissue 
abscesses 4.2%, acute otitis- 1.9%, pyelonephritis 0.8%, 
viral infection 3.1%. FUO was found in 45.3% of cases. 
Pathogens (91 strains) isolated from blood (and central 
venous catheters) for the last 10 years were: Gram (+) 
64%, Gram (-) 29%, Fungi 7%. CNS were isolated 
in 64%, Streptococcus spp. in 14%, S.aureus in 22% of 
cases among Gram (+) pathogens. Gram (-) strains 
were: KES 41%, P aeruginosa 23%, other 36%. Fungi 
consisted of Candida spp. mainly, Aspergillus spp. were 
found in 5.9% of cases. The number of MRSA and MR- 
CNS isolated from all pathological materials were 25% 
and 70%. The level of this pathogens was significantly 
higher (p<O,OOl)in 1990-1995 than in 1996-2000: 9% vs 
25% for MRSA and 7% vs 70% for MR-CNS. For the 
empirical treatment of FN standard antimicrobial 
regimens were used: 1st line carbapenems or ceftazidime 
or cefepime, 2nd line vancomicin, 3rd line ampho B were 
used in recommended for this patients doses. Clinical 
efficacy of the 1st line was: 57% and 60% ( ALL) vs 31% 
and 33% (AML) after cephalosporin’s 3-4 generation 
and carbapenem’s used respectively. The clinical result 
for the 2nd line was: 28% for ALL and 50% for AML. 
The 3rd line of therapy demonstrated very high response 
rate for ampho B: 91% for ALL and 80% for AML. 32% 
of children with AML and 5.2% children with ALL died 
because of sepsis. The investigation of viral infections 
shows that 100% of patients were infected with VEB 
and HV-6 type with a clinical symptoms in 23.8% of 
them. 4.8% of patients were infected by CMV. The 
treatment with ganciclovir was successful in all cases. 
Thus, abovementioned treatment of FN in children 
with ALL and AML show very high efficacy of this 
treatment. Very high rate of death for AML children 
make sense that the combination of vancomycin and 
ampho B at the 2nd line of therapy are useful. 
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Resistance patterns of 822 strains of P aeruginosa iso- 
lated from cancer patients in 1996-2001 were analysed. 
Resistance to widely used antimicrobial - ceftazidime 
(CAZ) - was 29.5% in 1996-1997; 31.5% in 1998-1999 
and 22.3% in 2000-2001 (p<O.Ol-0.001). Decreasing 
of resistance level to CAZ may be explained by in- 
creasing usage of cefepime (CPM) in the last 2.5 years. 
Resistance of I! aeruginosa to CPM in 2000-2001 didn’t 
differ significantly from that of CAZ (17.2% vs 22.3%, 
p>O.O5). Imipenem (IMP) in 2000-2001 was significantly 
more active compared to CAZ (12.9% vs 22.3%, 
p<O.OOOl). Higher level of resistance of P aeruginosa 
compared to CAZ was seen in 2000-2001 to cefo- 
perazone (49.4% vs 22.3%,p<O.OOOl),amikacin (43.0% 
vs 22.3%, p<O.OOOl), ciprofloxacin (57.5% vs 22.3%, 
p<O,OOOl) andmeropenem (39.3% vs22.3%,p<O.O001). 
Resistance rate to last three antimicrobials increased 
during last 6 years: amikacin - from 16.7% to 43.0%, 
ciprofloxacin - from 28.9% to 57.5%) and meropenem 
-from 17.8% to 39.3% (p<O.OOOl for all comparisons). 
Resistance rate of I! aeruginosa to CAZ during 
2000-2001 was the highest in ICU compared to all 
departments of the hospital (33.3% vs 22.3%,p<O.O1). 
Higher rate of resistant strains of P aeruginosa was 
found in 2000-2001 in bronchoscopic materials (34.3%, 
~~0.02) than in other ones. Thus, the surveillance 
data show that only three from above mentioned 
antimicrobials (CAZ, CPM, IMP) maintain their activity 
against P aeruginosa strains isolated from cancer patients 
in our hospital. Massive usage of other antibiotics such 
as amikacin, ciprofloxacin and meropenem resulted 
in progressive loss of susceptibility to them. Probably 
rational restriction policy is needed. 
